EPINEPHRINE

Peak

epinephrine

NDAINTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUSSOLUTION
Approved
Jul 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
13

Mechanism of Action

Adrenergic alpha-Agonists

Pharmacologic Class:

alpha-Adrenergic Agonist

Clinical Trials (5)

NCT06464510Phase 3Recruiting

Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis

Started Nov 2024
2,800 enrolled
Septic Shock
NCT06568367Phase 3Recruiting

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

Started Aug 2024
520 enrolled
Excessive SleepinessShift-work Disorder
NCT06413433Phase 3Recruiting

Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

Started Apr 2024
450 enrolled
Binge-Eating Disorder
NCT06360419Phase 3Completed

Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol

Started Mar 2024
346 enrolled
Major Depressive Disorder
NCT06013150Phase 1Completed

Study of Inhaled DMC-IH1 and Intramuscular (EpiPen®) Epinephrine in Healthy Male and Female Participants.

Started Oct 2023
24 enrolled
Anaphylactic Reaction